Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WT-1 and PRAME RNA-loaded dendritic cells
- Development stage
- Unknown
- Lead developer
- MediGene
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
WT-1 and PRAME RNA-loaded dendritic cells (FDC101) is an autologous, RNA-loaded mature dendritic cell (mDC) cancer vaccine. It is designed as a maintenance therapy for patients with acute myeloid leukemia (AML) who are in complete remission but ineligible for allogeneic hematopoietic stem cell transplantation. The vaccine is produced by loading a patient's own dendritic cells with full-length mRNA encoding two leukemia-associated antigens: Wilms' Tumor 1 (WT-1) and PRAME (Preferentially Expressed Antigen in Melanoma). These cells are matured using a TLR 7/8 agonist cocktail. Upon intradermal administration, the vaccine aims to prime and expand T-cell responses against residual leukemic cells expressing these antigens, thereby preventing relapse.
- Other names
- WT-1 and PRAME RNA-loaded DCsWT1 and PRAME RNA-loaded DCsWT 1 and PRAME RNA-loaded DCsFast-DC Immunotherapy
02
Targets
Preferentially expressed antigen in melanoma (PRAME) peptide-HLA complexWT1-pMHC (Wilms' tumor 1 peptide-HLA complex)
Beyond the preview
Go deeper on WT-1 and PRAME RNA-loaded dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WT-1 and PRAME RNA-loaded dendritic cells.